GlassScriptPhysician profile
Shalini Chitneni
NPI 1396951299
$45,716.99
in general payments reported to CMS, 2019-2025
60 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $1,197 · 2021: $5,557 · 2022: $13K · 2023: $15K · 2024: $7,491 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Consulting Fee: $5,440 · Food and Beverage: $4,805 · Long Term Medical Supply Or Device Loan: $881 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,917.00 |
| Consulting Fee | $5,440.00 |
| Food and Beverage | $4,805.24 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $230.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $27,998.00 | 2021-2024 | |
| Daiichi Sankyo INC. | $4,111.37 | 2020-2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $2,236.73 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,484.10 | 2021-2025 | |
| Seagen INC. | $1,476.79 | 2020-2023 | Adcetris, Tukysa, Padcev |
| Incyte Corporation | $986.67 | 2020-2025 | Jakafi, Monjuvi |
| Amgen INC. | $802.63 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $786.11 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $689.97 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $572.14 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Genzyme Corporation | $409.68 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $370.54 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $327.90 | 2019-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $312.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.00 | 2019-2023 | Alunbrig, Iclusig, Vpriv |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $260.06 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Genentech USA, INC. | $248.23 | 2019-2025 | Tecentriq, Phesgo, Lunsumio |
| Gilead Sciences, INC. | $209.14 | 2021-2025 | Trodelvy |
| Eisai INC. | $193.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $192.45 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $132.40 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $115.95 | 2023-2025 | Clonoseq |
| Abbvie INC. | $112.78 | 2023-2025 | Venclexta |
| Emd Serono, INC. | $107.81 | 2023-2025 | Bavencio |
| Array Biopharma INC | $102.76 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Foundation Medicine, INC. | $98.46 | 2020 | |
| Exelixis INC. | $74.67 | 2019-2022 | |
| Kite Pharma, INC. | $68.70 | 2021-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $66.57 | 2021-2025 | Qinlock |
| Lilly USA, LLC | $59.48 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $54.88 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sobi, INC | $53.42 | 2022-2023 | |
| Coherus Oncology, INC. | $45.65 | 2022-2024 | |
| Astellas Pharma US INC | $43.33 | 2023-2025 | Vyloy, Xospata |
| Alnylam Pharmaceuticals INC. | $40.22 | 2023 | Onpattro, Givlaari |
| Bayer Healthcare Pharmaceuticals INC. | $37.04 | 2025 | |
| Beone Medicines USA, INC. | $35.53 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $29.41 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $26.55 | 2024 | Tazverik |
| Morphosys, US INC. | $25.25 | 2021-2022 | |
| Teleflex LLC | $24.17 | 2025 | Arrow |
| Caris Mpi, INC. | $23.18 | 2025 | Mi Cancer Seek |
| Novocure INC. | $22.50 | 2024 | Optune Lua (Novottf-200t) |
| Pharmaessentia USA Corporation | $20.01 | 2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Legend Biotech USA INC. | $19.86 | 2025 | Carvykti |
| G1 Therapeutics, INC. | $19.32 | 2023 | Cosela |
| Aadi Bioscience, INC. | $19.18 | 2023 | Fyarro |
| Genmab U.S., INC. | $18.22 | 2025 | Tivdak |
| Janssen Pharmaceuticals, INC | $17.59 | 2023 | Xarelto |
| Cti Biopharma Corp. | $16.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.38 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $16.21 | 2019 | |
| Immunocore Limited | $16.02 | 2025 | Kimmtrak |
| Progenics Pharmaceuticals, INC. | $15.59 | 2025 | |
| Global Blood Therapeutics, INC. | $14.10 | 2022 | |
| Shire North American Group INC | $13.83 | 2019 | |
| Tersera Therapeutics LLC | $13.47 | 2023 | Zoladex |
| Dova Pharmaceuticals | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalini Chitneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.